Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy

Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy

Relatlimab is a type of human immunoglobulin G4 monoclonal blocking antibody. It is the world’s first Lymphocyte-Activation Gene-3 (LAG-3) inhibitor and the third immune checkpoint inhibitor with clinical application, following PD-1 and CTLA-4. Relatlimab can bind to the LAG-3 receptor which blocks...

Full description

Bibliographic Details
Main Authors: Jingjing Su, Yiting Fu, Zitong Cui, Zain Abidin, Jingsong Yuan, Xinmiao Zhang, Runmin Li, Chunzhen Zhao
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Pharmacology
Subjects:
relatlimab
LAG-3 inhibitor
nivolumab
metastatic melanoma
immune checkpoint
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1349081/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1349081/full

Similar Items